Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality, day 90 -15% Improvement Relative Risk Mortality, day 28 10% Viral clearance 24% c19hcq.org Ader et al. HCQ for COVID-19 RCT LATE TREATMENT Favors HCQ Favors control
An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-beta-1a and hydroxychloroquine in hospitalized patients with COVID-19 - Final results from the DisCoVeRy trial
Ader et al., medRxiv, doi:10.1101/2022.02.16.22271064 (Preprint)
6 Oct 2020    Source   PDF   Share   Tweet
Early terminated very late stage (95% on oxygen at baseline) DISCOVERY trial. 4% more patients were on ventilation at baseline in the HCQ group. This preprint presents more recent results than the earlier journal article.
risk of death, 15.3% higher, RR 1.15, p = 0.70, treatment 11 of 150 (7.3%), control 13 of 149 (8.7%), adjusted per study, odds ratio converted to relative risk, day 90.
risk of death, 10.1% lower, RR 0.90, p = 0.75, treatment 15 of 150 (10.0%), control 13 of 149 (8.7%), adjusted per study, odds ratio converted to relative risk, day 28.
risk of no viral clearance, 23.8% lower, RR 0.76, p = 0.68, treatment 4 of 83 (4.8%), control 5 of 81 (6.2%), NNT 74, odds ratio converted to relative risk, Table S2, day 29.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in the after exclusion results of meta analysis: very late stage, >50% on oxygen/ventilation at baseline.
Ader et al., 6 Oct 2020, Randomized Controlled Trial, multiple countries, preprint, baseline oxygen required 95.4%, 59 authors, study period 22 March, 2020 - 29 June, 2020, average treatment delay 9.0 days.
Contact: florence.ader@chu-lyon.fr.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit